Pivotal Ajovy data published in NEJM
Israeli pharma and generics player Teva (NYSE: TEVA), says the New England Journal of Medicine has published Phase III data from the SPACE trial showing Ajovy (fremanezumab-vfrm) reduced monthly migraine days and monthly headache days in children and adolescents with episodic migraine versus placebo.
Over 12 weeks, Ajovy cut monthly migraine days by 2.5 versus 1.4 days for placebo, and monthly headache days of at least moderate severity by 2.6 versus 1.5 days. Teva also reported a higher rate of at least 50% reduction in monthly migraine days with Ajovy than placebo.
Teva said no new safety signals were identified and the profile was consistent with adult studies. The company framed the publication as reinforcing evidence behind the pediatric label it won last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze